Okabena Investment Services Inc. Purchases Shares of 79,072 Cryoport, Inc. (NASDAQ:CYRX)

Okabena Investment Services Inc. acquired a new position in shares of Cryoport, Inc. (NASDAQ:CYRX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 79,072 shares of the company’s stock, valued at approximately $615,000. Okabena Investment Services Inc. owned 0.16% of Cryoport at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CYRX. Avanza Fonder AB acquired a new stake in Cryoport during the 4th quarter worth about $64,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cryoport during the third quarter worth about $82,000. Intech Investment Management LLC purchased a new stake in Cryoport in the third quarter valued at approximately $105,000. Olympiad Research LP purchased a new stake in Cryoport in the fourth quarter valued at approximately $103,000. Finally, Fox Run Management L.L.C. acquired a new position in Cryoport in the 4th quarter worth approximately $111,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Stock Performance

Shares of NASDAQ CYRX opened at $6.09 on Friday. Cryoport, Inc. has a 1 year low of $4.58 and a 1 year high of $20.11. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The company’s fifty day moving average price is $6.68 and its 200 day moving average price is $7.32. The company has a market capitalization of $303.95 million, a PE ratio of -1.80 and a beta of 1.67.

Cryoport (NASDAQ:CYRX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The business had revenue of $59.53 million for the quarter, compared to analyst estimates of $58.71 million. During the same quarter last year, the business earned ($0.29) earnings per share. On average, research analysts predict that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Analyst Ratings Changes

CYRX has been the topic of several recent research reports. Guggenheim initiated coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Cryoport in a research report on Wednesday, March 5th. Finally, UBS Group raised Cryoport from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Monday, March 24th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Cryoport currently has an average rating of “Moderate Buy” and an average price target of $11.67.

Insider Buying and Selling at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 19,830 shares of company stock valued at $118,353. Company insiders own 10.10% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.